Bronchiectasis — a chronic, progressive lung condition marked by permanently dilated airways — has long puzzled clinicians with its striking female predominance after menopause. New evidence from one of the largest postmenopausal cohorts ever assembled now points to estrogen exposure duration as a meaningful biological variable in that sex-based disparity, reframing what has often been treated as a purely pulmonary disease.
Drawing on nearly 97,000 women enrolled in the Women's Health Initiative and tracked through Medicare claims data, this analysis examined how the span between menarche and menopause — the reproductive lifespan — relates to incident bronchiectasis. Women whose reproductive window extended 40 or more years carried a 12% lower adjusted risk compared with those whose window lasted under 30 years (aHR 0.88, 95% CI: 0.77–0.99). The association was not uniform: hormone therapy (HT) acted as a significant effect modifier. Among women who never used HT, the protective gradient of a longer reproductive lifespan was amplified — conferring roughly a 22% risk reduction for those in the longest exposure category. In women who did use HT, no statistically significant trend emerged, suggesting exogenous estrogen may partially compensate for a shortened endogenous window.
These findings align with a growing body of evidence implicating sex hormones in airway biology. Estrogen influences mucociliary clearance, airway inflammation, and immune modulation — all pathways implicated in bronchiectasis pathogenesis. Earlier research has connected early menopause to adverse pulmonary outcomes including accelerated lung function decline and COPD risk, but the bronchiectasis link has been underexplored. The study's strengths include its scale and prospective design, but the observational framework prevents causal inference, and Medicare-based diagnosis capture may miss mild cases. Reproductive lifespan also serves as a proxy for cumulative estrogen exposure rather than a direct hormonal measure. Still, the HT interaction finding adds biological plausibility and points toward endocrine-pulmonary pathways as a viable target for future mechanistic and interventional research.